Pathogenesis and treatment of leukemia: An Asian perspective

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Natural killer cell leukemia; T cell large granular lymphocyte leuekemia

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STEROID; THYMOCYTE ANTIBODY;

ACUTE PROMYELOCYTIC LEUKEMIA DIFFERENTIATION SYNDROME; AGGRESSIVE NK CELL LEUKEMIA; AREA UNDER THE CURVE; ASIAN; BLEEDING; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER THERAPY; CARDIOTOXICITY; CHINA; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; ETHNIC DIFFERENCE; HEART VENTRICLE ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LEUKEMOGENESIS; LEUKOCYTOSIS; LOW DRUG DOSE; LUNG INFILTRATE; NEUTROPENIA; NK T CELL LYMPHOMA; PROMYELOCYTIC LEUKEMIA; PURE RED CELL ANEMIA; QT PROLONGATION; RARE DISEASE; RECIPROCAL CHROMOSOME TRANSLOCATION; RECURRENT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SPLENOMEGALY; T CELL LEUKEMIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ARSENICALS; ASIAN CONTINENTAL ANCESTRY GROUP; CELL PROLIFERATION; HUMANS; LEUKEMIA; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RECURRENCE; TRETINOIN;

EID: 84857579198     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.621418     Document Type: Review

References (37)

1. Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol 2010;47(Suppl 1):S5-7
2. Kwong YL, Wong KF, Chan LC, et al. The spectrum of chronic lymphoproliferative disorders in Chinese people. An analysis of 64 cases. Cancer 1994;74:174-81 (Pubitemid 24187627)
3. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15
4. Kwong YL, Au WY, Leung AY, Tse EW. T-cell large granular lymphocyte leukemia: an Asian perspective. Ann Hematol 2010;89:331-9
5. Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol 2010;3:593-602 . A comprehensive review of NK cell malignancies.
6. Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia 1994;8(Suppl 2):S20-6
7. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72
8. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91 . A comprehensive review of the management of acute promyelocytic leukemia.
9. Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, et al. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant 2007;13:997-1004 (Pubitemid 47240750)
10. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 1992;12:170-2
11. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53 (Pubitemid 27229821)
12. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60
13. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010;328:240-3
14. Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002;58:521-6 (Pubitemid 35435505)
15. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 2006;108:103-6 (Pubitemid 43990617)
16. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133:881-5
17. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997;89:3487-8
18. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003;102:407-8 (Pubitemid 36759684)
19. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009;106:3342-7
20. Leung J, Pang A, Yuen WH, et al. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 2007;109:740-6 (Pubitemid 46105976)
21. Au WY, Chim CS, Lie AK, et al. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002;117:130-2 (Pubitemid 34304431)
22. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-68 (Pubitemid 35424755)
23. Berenson JR, Matous J, Swift RA, et al. A Phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007;13:1762-8 (Pubitemid 46952943)
24. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495-503
25. Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist 2006;11:263-73
26. Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol 2011;152:273-83
27. Tse E, Chan JC, Pang A, et al. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia 2007;21:2225-6 (Pubitemid 47423825)
28. Rosenblum MD, LaBelle JL, Chang C, et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood 2004;103:1969-71 (Pubitemid 38269004)
29. Au WY, Lam CC, Chim CS, et al. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005;29:1213-15 (Pubitemid 41169238)
30. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002;17:539-54 (Pubitemid 34411212)
31. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94
32. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency of Research on Cancer; Lyon: 2008. p. 285-9
33. Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggressive NK-cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency of Research on Cancer; Lyon: 2008. p. 276-7
34. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016-20 (Pubitemid 351997606)
35. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005;130:561-7 (Pubitemid 43899760)
36. Iqbal J, Weisenburger DD, Chowdhury A, et al. International Peripheral T-cell Lymphoma Project. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011;25:348-58
37. Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2011;223:496-510